IP Library Granted Patent US 8,288,385
Granted Patent B2
US 8,288,385 · App. 13/263,089 · Granted Oct 16, 2012

6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,288,385
App. No.
13/263,089
Granted
Oct 16, 2012
Kind
B2
Abstract

The present invention relates to 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidine derivatives and their use as P2Y 12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

Claims (99)

1. A compound of formula I

wherein

R 1 represents phenyl which is unsubstituted or mono-, di- or tri-substituted, wherein the substituents are independently selected from the group consisting of halogen, (C 1 -C 4 )alkyl and (C 1 -C 3 )fluoroalkyl;

Z represents hydrogen, (C 1 -C 4 )alkyl, cyclopropyl, cyclopropylmethyl, hydroxy-(C 1 -C 3 )alkyl, carboxy-(C 1 -C 3 )alkyl, cyano-(C 1 -C 3 )alkyl, P(O)(R 6 ) 2 —(C 1 -C 3 )alkyl, 1H-tetrazol-5-yl-(C 1 -C 3 )alkyl or benzyl;

R 2 represents cyano, —COOH, —CONH 2 , —COOR 3 , hydroxy-(C 1 -C 3 )alkyl, (C 1 -C 2 )alkoxy-(C 1 -C 2 )alkyl, carboxy-(C 1 -C 3 )alkyl, 1H-tetrazol-5-yl or —NHR 5 ;

with the proviso that, if R 2 represents —COOR 3 , Z represents carboxy-(C 1 -C 3 )alkyl or P(O)(R 6 ) 2 —(C 1 -C 3 )alkyl;

R a represents hydrogen or methyl;

R 3 represents (C 1 -C 4 )alkyl;

R 4 represents (C 1 -C 6 )alkoxy or benzyloxy;

R 5 represents hydrogen or tert-butoxycarbonyl;

R 6 represents hydroxy, (C 1 -C 4 )alkoxy, R 7 —OCH 2 O— or R 8 —(C 1 -C 4 )alkyl-NH—;

R 7 represents (C 1 -C 4 )alkylcarbonyl or (C 1 -C 4 )alkoxycarbonyl; and

R 8 represents (C 1 -C 4 )alkoxycarbonyl;

or a salt of such a compound.

2. The compound of formula I according to claim 1 , wherein

R 1 represents phenyl which is unsubstituted or mono-substituted with fluorine, methyl or trifluoromethyl;

Z represents hydrogen, (C 1 -C 4 )alkyl, cyclopropyl, 1-hydroxy-ethyl, 2-carboxy-ethyl, cyano-methyl, or 2-(1H-tetrazol-5-yl)-ethyl;

R 2 represents cyano, —COOH, —CONH 2 , hydroxy-methyl, methoxy-methyl, carboxy-methyl, 2-carboxy-ethyl, 1H-tetrazol-5-yl or —NHR 5 ;

R a represents hydrogen;

R 4 represents (C 1 -C 6 )alkoxy; and

R 5 represents hydrogen or tert-butoxycarbonyl;

or a salt of such a compound.

3. The compound of formula I according to claim 1 , wherein R 1 represents phenyl which is unsubstituted or mono-substituted with halogen, (C 1 -C 2 )alkyl or trifluoromethyl;

or a salt of such a compound.

4. The compound of formula I according to claim 1 , wherein Z represents hydrogen, (C 1 -C 4 )alkyl, cyclopropyl, cyclopropylmethyl, hydroxy-(C 1 -C 2 )alkyl, carboxy-(C 1 -C 2 )alkyl, cyano-(C 1 -C 2 )alkyl, P(O)(R 6 ) 2 —(C 1 -C 2 )alkyl, 1H-tetrazol-5-yl-(C 1 -C 2 )alkyl or benzyl;

or a salt of such a compound.

5. The compound of formula I according to claim 1 , wherein Z represents P(O)(R 6 ) 2 —(C 1 -C 2 )alkyl;

or a salt of such a compound.

6. The compound of formula I according to claim 1 , wherein R 2 represents cyano, —COOH, —CONH 2 , hydroxy-methyl, methoxy-methyl, carboxy-methyl, 2-carboxy-ethyl, 1H-tetrazol-5-yl or —NHR 5 ;

or a salt of such a compound.

7. The compound of formula I according to claim 1 , wherein R a represents hydrogen;

or a salt of such a compound.

8. The compound of formula I according to claim 1 , wherein R 4 represents (C 1 -C 6 )alkoxy;

or a salt of such a compound.

9. The compound of formula I according to claim 5 , wherein R 6 represents hydroxy, R 7 —OCH 2 O— or R 8 —(C 1 -C 4 )alkyl-NH—;

or a salt of such a compound.

10. The compound of formula I according to claim 9 , wherein R 7 represents (C 1 -C 2 )alkylcarbonyl or (C 1 -C 2 )alkoxycarbonyl;

or a salt of such a compound.

11. The compound of formula I according to claim 1 , which is selected from the group consisting of:

(1α,5α,6α)-3-{6-[(S)-1-(4-Butoxycarbonyl-piperazine-1-carbonyl)-3-carboxy-propylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6β)-3-{6-[(S)-1-(4-Butoxycarbonyl-piperazine-1-carbonyl)-3-carboxy-propylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6α)-3-{6-[(S)-1-(4-Butoxycarbonyl-piperazine-1-carbonyl)-3-carboxy-propylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid ethyl ester;

(1α,5α,6β)-3-{6-[(S)-1-(4-Butoxycarbonyl-piperazine-1-carbonyl)-3-carboxy-propylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid ethyl ester;

4-((S)-2-{[6-((1α,5α,6α)-6-tert-Butoxycarbonylamino-3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-4-carboxy-butyryl)-piperazine-1-carboxylic acid butyl ester;

4-((S)-2-{[6-((1α,5α,6β)-6-tert-Butoxycarbonylamino-3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-4-carboxy-butyryl)-piperazine-1-carboxylic acid butyl ester;

4-((S)-2-{[6-((1α,5α,6α)-6-Amino-3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-4-carboxy-butyryl)-piperazine-1-carboxylic acid butyl ester;

4-((S)-2-{[6-((1α,5α,6β)-6-Amino-3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-4-carboxy-butyryl)-piperazine-1-carboxylic acid butyl ester;

4-((S)-4-Carboxy-2-{[6-((1α,5α,6α)-6-hydroxymethyl-3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-butyryl)-piperazine-1-carboxylic acid butyl ester;

4-((S)-4-Carboxy-2-{[6-((1α,5α,6α)-6-methoxymethyl-3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-butyryl)-piperazine-1-carboxylic acid butyl ester;

(1α,5α,6β)-3-{6-[(S)-1-(4-Butoxycarbonyl-piperazine-1-carbonyl)-2-methyl-propylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6α)-3-{6-[(S)-1-(4-Butoxycarbonyl-piperazine-1-carbonyl)-2-methyl-propylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6β)-3-{6-[(S)-1-(4-Ethoxycarbonyl-piperazine-1-carbonyl)-2-methyl-propylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6β)-3-{6-[(S)-2-Methyl-1-(4-propoxycarbonyl-piperazine-1-carbonyl)-propylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6β)-3-{6-[(S)-2-Methyl-1-(4-pentyloxycarbonyl-piperazine-1-carbonyl)-propylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6β)-3-{6-[(S)-1-(4-Hexyloxycarbonyl-piperazine-1-carbonyl)-2-methyl-propylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

4-((S)-2-{[6-((1α,5α,6α)-6-Carbamoyl-3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-methyl-butyryl)-piperazine-1-carboxylic acid butyl ester;

4-((S)-2-{[6-((1α,5α,6α)-6-Cyano-3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-methyl-butyryl)-piperazine-1-carboxylic acid butyl ester;

4-[(S)-3-Methyl-2-({2-phenyl-6-[(1α,5α,6α)-6-(1H-tetrazol-5-yl)-3-aza-bicyclo[3.1.0]hex-3-yl]-pyrimidine-4-carbonyl}-amino)-butyryl]-piperazine-1-carboxylic acid butyl ester;

4-((S)-2-{[6-((1α,5α,6β)-6-Carbamoyl-3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-methyl-butyryl)-piperazine-1-carboxylic acid butyl ester;

4-((S)-2-{[6-((1α,5α,6β)-6-Cyano-3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-methyl-butyryl)-piperazine-1-carboxylic acid butyl ester;

4-[(S)-3-Methyl-2-({2-phenyl-6-[(1α,5α,6β)-6-(1H-tetrazol-5-yl)-3-aza-bicyclo[3.1.0]hex-3-yl]-pyrimidine-4-carbonyl}-amino)-butyryl]-piperazine-1-carboxylic acid butyl ester;

4-((S)-2-{[6-((1α,5α,6β)-6-Amino-3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-methyl-butyryl)-piperazine-1-carboxylic acid butyl ester;

4-((S)-2-{[6-((1α,5α,6α)-6-Carboxymethyl-3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-methyl-butyryl)-piperazine-1-carboxylic acid butyl ester;

4-((S)-2-{[6-((1α,5α,6β)-6-Carboxymethyl-3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-methyl-butyryl)-piperazine-1-carboxylic acid butyl ester;

4-[(S)-2-({6-[(1α,5α,6β)-6-(2-Carboxy-ethyl)-3-aza-bicyclo[3.1.0]hex-3-yl]-2-phenyl-pyrimidine-4-carbonyl}-amino)-3-methyl-butyryl]-piperazine-1-carboxylic acid butyl ester;

4-[(S)-2-({6-[(1α,5α,6α)-6-(2-Carboxy-ethyl)-3-aza-bicyclo[3.1.0]hex-3-yl]-2-phenyl-pyrimidine-4-carbonyl}-amino)-3-methyl-butyryl]-piperazine-1-carboxylic acid butyl ester;

(1α,5α,6β)-3-[6-[(S)-1-(4-Butoxycarbonyl-piperazine-1-carbonyl)-2-methyl-propylcarbamoyl]-2-(4-fluoro-phenyl)-pyrimidin-4-yl]-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6β)-3-{6-[(S)-1-(4-Butoxycarbonyl-piperazine-1-carbonyl)-2-methyl-propylcarbamoyl]-2-p-tolyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6β)-3-[6-[(S)-1-(4-Butoxycarbonyl-piperazine-1-carbonyl)-2-methyl-propylcarbamoyl]-2-(3-trifluoromethyl-phenyl)-pyrimidin-4-yl]-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6β)-3-{6-[(S)-1-((R)-4-Butoxycarbonyl-3-methyl-piperazine-1-carbonyl)-2-methyl-propylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6β)-3-{6-[(S)-1-((R)-4-Benzyloxycarbonyl-3-methyl-piperazine-1-carbonyl)-2-methyl-propylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6β)-3-{6-[2-(4-Butoxycarbonyl-piperazin-1-yl)-2-oxo-ethylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6α)-3-{6-[(S)-2-(4-Butoxycarbonyl-piperazin-1-yl)-1-methyl-2-oxo-ethylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6β)-3-{6-[(S)-2-(4-Butoxycarbonyl-piperazin-1-yl)-1-methyl-2-oxo-ethylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6β)-3-{6-[(S)-1-(4-Butoxycarbonyl-piperazine-1-carbonyl)-propylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6β)-3-{6-[(S)-1-(4-Butoxycarbonyl-piperazine-1-carbonyl)-butylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6β)-3-{6-[(S)-1-(4-Butoxycarbonyl-piperazine-1-carbonyl)-pentylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6β)-3-{6-[(S)-1-(4-Butoxycarbonyl-piperazine-1-carbonyl)-3-methyl-butylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6β)-3-{6-[(S)-2-(4-Butoxycarbonyl-piperazin-1-yl)-1-cyclopropylmethyl-2-oxo-ethylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6β)-3-{6-[(S)-2-(4-Butoxycarbonyl-piperazin-1-yl)-1-cyclopropyl-2-oxo-ethylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6β)-3-{6-[(1S,2R)-1-(4-Butoxycarbonyl-piperazine-1-carbonyl)-2-hydroxy-propylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6β)-3-{6-[(S)-1-(4-Butoxycarbonyl-piperazine-1-carbonyl)-2,2-dimethyl-propylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6α)-3-{6-[(S)-1-(4-Butoxycarbonyl-piperazine-1-carbonyl)-2,2-dimethyl-propylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6β)-3-{6-[(S)-1-Benzyl-2-(4-butoxycarbonyl-piperazin-1-yl)-2-oxo-ethylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6α)-3-{6-[(S)-1-Benzyl-2-(4-butoxycarbonyl-piperazin-1-yl)-2-oxo-ethylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6β)-3-[6-[(S)-1-(4-Butoxycarbonyl-piperazine-1-carbonyl)-2-methyl-propylcarbamoyl]-2-(2-fluoro-phenyl)-pyrimidin-4-yl]-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6β)-3-{6-[(S)-1-(4-Butoxycarbonyl-piperazine-1-carbonyl)-2-cyano-ethylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6β)-3-{6-[(S)-1-(4-Butoxycarbonyl-piperazine-1-carbonyl)-3-(1H-tetrazol-5-yl)-propylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid;

(1α,5α,6α)-3-{6-[(R)-2-(4-Butoxycarbonyl-piperazin-1-yl)-1-(diethoxy-phosphorylmethyl)-2-oxo-ethylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid ethyl ester;

(1α,5α,6α)-3-{6-[(R)-2-(4-Butoxycarbonyl-piperazin-1-yl)-2-oxo-1-phosphonomethyl-ethylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid ethyl ester;

(1α,5α,6α)-3-{6-[(R)-1-(Bis-(acetoxymethoxy)-phosphorylmethyl)-2-(4-butoxycarbonyl-piperazin-1-yl)-2-oxo-ethylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid ethyl ester;

N,N′-Bis-((S)-1-Ethoxycarbonylethyl)-(R)-2-[(4-[(1α,5α,6α)-6-ethoxycarbonyl-3-aza-bicyclo[3.1.0]hex-3-yl]-2-phenyl-pyrimidin-6-carbonyl)-amino]-3-oxo-3-(4-butoxy-carbonyl-piperazin-1-yl)-propyl-phosphonic acid diamide; and

(1α,5α,6α)-3-{6-[(R)-1-(Bis-(ethoxycarbonyloxymethoxy)-phosphorylmethyl)-2-(4-butoxycarbonyl-piperazin-1-yl)-2-oxo-ethylcarbamoyl]-2-phenyl-pyrimidin-4-yl}-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid ethyl ester;

or a salt of such a compound.

12. A pharmaceutical composition containing at least one compound of formula I as defined in claim 1 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.

13. A method for the treatment of myocardial infarction, arterial thrombosis, transient ischaemic attacks, peripheral vascular disease and stable and unstable angina comprising the administration to a patient in need thereof an effective amount of a compound of formula I according to claim 1 , in free or pharmaceutically acceptable salt of such a compound.

14. A method for the treatment of myocardial infarction, arterial thrombosis, transient ischaemic attacks, peripheral vascular disease and stable and unstable angina comprising the administration to a patient in need thereof an effective amount of a compound according to claim 11 , in free or pharmaceutically acceptable salt of such a compound.

15. A method for the treatment of thrombosis comprising the administration to a patient in need thereof an effective amount of a compound of formula I according to claim 1 , in free or pharmaceutically acceptable salt of such a compound.

16. A method for the treatment of thrombosis comprising the administration to a patient in need thereof an effective amount of a compound according to claim 11 , in free or pharmaceutically acceptable salt of such a compound.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2024
From: IDORSIA PHARMACEUTICALS LTD.
To: VIATRIS ASIA PACIFIC PTE. LTD.
Reel/Frame 067647/0303 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 042464 FRAME: 0407. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 28, 2017
From: ACTELION PHARMACEUTICALS LTD
To: IDORSIA PHARMACEUTICALS LTD
Reel/Frame 043017/0022 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2017
From: ACTELION PHARMACEUTICALS LTD
To: IDORSIA PHARMACEUTICALS LTD
Reel/Frame 042464/0407 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2012
From: CAROFF, EVA; HILPERT, KURT; HUBLER, FRANCIS; MEYER, EMMANUEL; RENNEBERG, DORTE
To: ACTELION PHARMACEUTICALS LTD.
Reel/Frame 028398/0773 →